Company intelligence / Profile preview

Oxtra Pharmaceuticals

Doylestown, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Oxtra Pharmaceuticals is a biotechnology company focused on developing innovative therapies for maternal health, specifically targeting conditions related to labor and delivery. The company's primary focus is on the development of OX-101, a novel, potent, and selective oxytocin receptor agonist designed to prevent and treat postpartum hemorrhage. By leveraging advanced medicinal chemistry, Oxtra aims to provide safer and more effective pharmacological options for obstetric care. The company is currently advancing its lead candidate through pre-clinical development with the goal of improving outcomes for mothers globally.

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Oxtra Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxtra Pharmaceuticals.

Explore the full profile